The strategy behind IDT’s move into specialty generics




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: The strategy behind IDT’s move into specialty generics
Released on: December 08, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    IDT have over 30 years of experience in contract manufacturing.
  • Summary
  • Transcript
  • Participants
  • Company
IDT have over 30 years of experience in contract manufacturing. Paul MacLeman, CEO to IDT Australia, explains how IDT Australia are turning their expertise toward a new specialty generics business.
IDT have over 30 years of experience in contract manufacturing. Paul MacLeman, CEO to IDT Australia, explains how IDT Australia are turning their expertise toward a new specialty generics business.
Dr. Paul MacLeman joined IDT in April 2013 as Chief Executive Officer. With a career spanning veterinary practice, the pharmaceutical/biotechnology and investment banking sectors, he has experience in business development, research management, technology commercialisation, staff development and sales and marketing. He has also founded life sciences startups in the biologics area and worked in investment banking focusing on the analysis and financing of technology companies.
For over 30 years, IDT Australia has brought our expertise and innovation to projects large and small. Our culture is built on the importance of quality, and we take pride that we have worked with nine of the top ten pharmaceutical companies providing a flexible, comprehensive service from early API and finished dose product development and clinical trial research through to commercial manufacture.